Nicholas Investment Partners, LP Argenx Se Transaction History

Nicholas Investment Partners, LP

$1.04 Billion
Q3 2025

A detailed history of Nicholas Investment Partners, LP transactions in Argenx Se stock. As of the latest transaction made, Nicholas Investment Partners, LP holds 8,254 shares of ARGX stock, worth $7.49 Million. This represents 0.59% of its overall portfolio holdings.

Number of Shares

8,254

Previous 8,254 -0.0%

Holding current value

$7.49 Million

Previous $4.55 Million 33.81%

% of portfolio

0.59%

Previous 0.5%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$571.0 - $671.75 $1,713 - $2,015	3 Added 0.04%	8,254 $4.89 Million
Q3 2024 Nov 12, 2024	BUY	$434.22 - $551.9 $3.58 Million - $4.55 Million	8,251 New	8,251 $4.47 Million
Q4 2023 Feb 07, 2024	SELL	$338.91 - $506.01 $26.3 Million - $39.3 Million	-77,647 Reduced 82.99%	15,919 $6.06 Million
Q3 2023 Nov 13, 2023	SELL	$369.35 - $548.43 $682,558 - $1.01 Million	-1,848 Reduced 1.94%	93,566 $46 Million
Q2 2023 Aug 09, 2023	SELL	$360.14 - $422.58 $8.36 Million - $9.81 Million	-23,211 Reduced 19.57%	95,414 $37.2 Million

Q1 2023 May 11, 2023	BUY	$334.23 - $403.65 $17.5 Million - $21.2 Million	52,480 Added 79.34%	118,625 $44.2 Million
Q4 2022 Feb 10, 2023	SELL	$342.17 - $402.31 $35,585 - $41,840	-104 Reduced 0.16%	66,145 $25.1 Million
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $4.73 Million - $5.45 Million	-13,776 Reduced 17.21%	66,249 $23.4 Million
Q2 2022 Aug 10, 2022	SELL	$269.58 - $378.88 $4.4 Million - $6.19 Million	-16,335 Reduced 16.95%	80,025 $30.3 Million
Q1 2022 May 10, 2022	BUY	$254.45 - $351.06 $5.33 Million - $7.35 Million	20,928 Added 27.74%	96,360 $30.4 Million
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $5.48 Million - $7.11 Million	20,134 Added 36.41%	75,432 $26.4 Million
Q3 2021 Nov 15, 2021	SELL	$295.0 - $350.58 $6.85 Million - $8.14 Million	-23,229 Reduced 29.58%	55,298 $16.7 Million
Q2 2021 Aug 10, 2021	SELL	$257.11 - $319.92 $1.95 Million - $2.43 Million	-7,601 Reduced 8.83%	78,527 $23.6 Million
Q1 2021 May 14, 2021	BUY	$268.3 - $380.31 $751,240 - $1.06 Million	2,800 Added 3.36%	86,128 $23.7 Million
Q4 2020 Feb 11, 2021	SELL	$248.13 - $308.36 $19,106 - $23,743	-77 Reduced 0.09%	83,328 $24.5 Million
Q3 2020 Nov 13, 2020	BUY	$215.51 - $272.51 $14.5 Million - $18.3 Million	67,170 Added 413.74%	83,405 $21.9 Million
Q2 2020 Aug 12, 2020	SELL	$127.44 - $232.72 $3.33 Million - $6.07 Million	-26,100 Reduced 61.65%	16,235 $3.66 Million
Q1 2020 May 13, 2020	BUY	$108.83 - $165.23 $112,421 - $170,682	1,033 Added 2.5%	42,335 $5.58 Million
Q4 2019 Feb 13, 2020	BUY	$106.59 - $164.21 $935,433 - $1.44 Million	8,776 Added 26.98%	41,302 $6.63 Million
Q3 2019 Nov 13, 2019	SELL	$113.31 - $150.51 $28,100 - $37,326	-248 Reduced 0.76%	32,526 $3.71 Million
Q2 2019 Aug 09, 2019	SELL	$115.0 - $141.58 $27,370 - $33,696	-238 Reduced 0.72%	32,774 $4.64 Million
Q1 2019 May 15, 2019	BUY	$98.85 - $134.59 $670,598 - $913,058	6,784 Added 25.87%	33,012 $4.12 Million
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $488,720 - $841,111	-7,659 Reduced 22.6%	26,228 $2.52 Million
Q3 2018 Nov 14, 2018	SELL	$75.5 - $96.63 $46,432 - $59,427	-615 Reduced 1.78%	33,887 $2.57 Million
Q2 2018 Aug 14, 2018	BUY	$74.84 - $100.16 $310,211 - $415,163	4,145 Added 13.65%	34,502 $2.86 Million
Q1 2018 May 15, 2018	SELL	$56.95 - $85.19 $1.05 Million - $1.58 Million	-18,516 Reduced 37.89%	30,357 $2.44 Million
Q4 2017 Feb 14, 2018	BUY	$22.57 - $63.56 $1.1 Million - $3.11 Million	48,873	48,873 $3.09 Million

Others Institutions Holding ARGX

# of Institutions

526

Shares Held

26M

Call Options Held

590K

Put Options Held

320K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $50.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Nicholas Investment Partners, LP with notifications on news.

Account

Nicholas Investment Partners, LP Argenx Se Transaction History